_
 

Oct 26, 2009
Cenix BioScience celebrates 10th anniversary 
Jun 15, 2009
Cenix BioScience expands relationship with AstraZeneca, signing multi-project research agreement ...
Mar 19, 2009
Cenix BioScience follows up successful RNAi-based target discovery screens with target validation study for AstraZeneca. ...


Apr 11 - 15, 2010, Phoenix, Arizona
SBS 16th Annual Conference & Exhibition (Advancing the Science of Drug Discovery) ...
Apr 11 - 16, 2010, Copper Mountain, CO
Keystone Symposia: Malaria - New Approaches to Understanding Host-Parasite Interactions ...

 
 
Cenix BioScience is a contract research organization focused on the discovery and pre-clinical development of novel therapeutics, specializing in advanced applications of RNA interference (RNAi) gene silencing combined with high content phenotyping in cultured cells in vitro and in animals in vivo.

Now in its 11th year, Cenix has built-up solid scientific and commercial track records, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields.

The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured human and rodent cells, and are now complemented by microRNA-focused experimentation and in vivo applications of synthetic siRNAs.

As such, Cenix is a mature, reliable, and fully-proven industrial research partner, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none worldwide.
 
© Cenix BioScience GmbH 2009. All rights reserved.